drugset / Trial / NCT00940212

Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 in Healthy Volunteers

NCT00940212 ↗

Phase 1 Completed 80 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindBasic science

Summary

The primary aim of this study is to investigate the safety and tolerability of AZD2423 single doses in healthy volunteers.

Timeline

Start
2009-07
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD2423 Unknown — Oral

Indications

No indication recorded.